
News|Articles|March 31, 2026
Q1 2026 recap: 6 FDA approvals pediatricians need to know
Author(s)Celeste Krewson, Assistant Editor
Fact checked by: Patrick Campbell, Yasmeen Qahwash
A review of 6 drugs approved by the FDA in Q1 2026, with links to coverage from Contemporary Pediatrics.
Advertisement
Advertisement
The first quarter of 2026 marked a period of profound advancement in pediatric health care, driven by a wave of FDA drug approvals that offer renewed hope for some of the most complex and rare pediatric conditions. From historic, first-of-their-kind systemic therapies for ultrarare disorders such as Menkes disease and Hunter syndrome to critical new interventions for achondroplasia and acquired hypothalamic
Related to this article

In SURMOUNT-ADOLESCENTS, tirzepatide cut BMI 18.5% at 72 weeks vs a 0.5% rise with placebo in adolescents with obesity.

Caregivers reported itch, symptom, and QOL gains with roflumilast cream 0.05% in infants with AD; an FDA decision is due February 2027.

In STEP Young, semaglutide cut BMI 13.5% at 68 weeks vs a 2.7% rise with placebo in children aged 6 to <12 years with obesity.

In a matched cohort of children aged 6 and younger with EoE, dupilumab was linked to less incident asthma than swallowed budesonide (10.5% vs 16.2%).

Full OptIMMize-1 results show high skin clearance rates with risankizumab in children and teens with psoriasis, sustained through 52 weeks.

Cenobamate sNDAs target PGTC seizures in patients ≥12 years and pediatric focal seizures; phase 3 PGTC data showed a 71.9% median reduction.

FDA approved Lupin's generic of Firdapse for LEMS in patients 6 years and older, but a patent settlement delays US marketing until at least 2035.
Advertisement
Advertisement

